Antimicrobial regimens | Total N (%) | 30-day mortality N (%) | P value |
---|---|---|---|
CAZ-AVI-containing regimen | 28 (29.8) | 2/28 (7.1) | 0.003 |
CAZ-AVI | 3 | 0 | Â |
CAZ-AVI + ATM | 7 | 0 |  |
CAZ-AVI + ATM + tigecycline | 10 | 0 |  |
CAZ-AVI + ATM + aminoglycoside | 2 | 0 |  |
CAZ-AVI + ATM + polymyxin | 2 | 1/2 |  |
CAZ-AVI + tigecycline | 4 | 1/4 |  |
OAAs regimen | 66 (70.2) | 25/66 (37.9) | Â |
Tigecycline-containing regimens | 44 (66.7) | 17/44 (38.6) | Â |
Tigecycline + aminoglycoside | 28 | 10/28 |  |
± carbapenem |  |  |  |
Tigecycline + aminoglycoside | 3 | 2/3 |  |
+fluoroquinolone | Â | Â | Â |
Tigecycline + fosfomycin | 2 | 0 |  |
Tigecycline + ATM | 1 | 0 |  |
Tigecycline ± carbapenem | 10 | 5/10 |  |
Polymyxin-containing regimens | 10 (15.2) | 4/10 (40) | Â |
Polymyxin + tigecycline + | 4 | 1/4 |  |
aminoglycoside/ fluoroquinolone | Â | Â | Â |
Polymyxin + tigecycline ± carbapenem | 3 | 2/3 |  |
Polymyxin + tigecycline + ATM | 2 | 0 |  |
Polymyxin alone | 1 | 1/1 | Â |
Others | 12 (18.2) | 4/12 (33.3) | Â |
Aminoglycoside ± carbapenem | 9 | 4/9 |  |
Fluoroquinolone + carbapenem | 2 | 0 |  |
Aminoglycoside + fluoroquinolone | 1 | 0 |  |
Monotherapy a | 25 (37.9) | 13/25 (52.0) | Â |
Combination therapy b | 41 (61.1) | 12/41 (29.3) | 0.065 |
Appropriate therapy started within 24Â h | Â | Â | 0.006 |
Yes | 49 (52.1) | 8/49 (16.3) | Â |
No | 45 (47.9) | 19/45 (42.2) | Â |
Appropriate therapy started within 48Â h | Â | Â | Â |
Yes | 83 (88.3) | 22/83 (26.5) | 0.192 |
No | 11 (11.7) | 5/11 (45.5) | Â |